Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Assets (2016 - 2025)

Historic Current Assets for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $1.0 billion.

  • Agios Pharmaceuticals' Current Assets fell 382.43% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 382.43%. This contributed to the annual value of $965.6 million for FY2024, which is 1580.23% up from last year.
  • Agios Pharmaceuticals' Current Assets amounted to $1.0 billion in Q3 2025, which was down 382.43% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Current Assets peaked at $2.4 billion during Q1 2021, and registered a low of $632.1 million during Q2 2024.
  • Moreover, its 5-year median value for Current Assets was $965.6 million (2024), whereas its average is $1.0 billion.
  • Per our database at Business Quant, Agios Pharmaceuticals' Current Assets skyrocketed by 30102.47% in 2021 and then crashed by 5859.46% in 2022.
  • Agios Pharmaceuticals' Current Assets (Quarter) stood at $1.1 billion in 2021, then fell by 21.75% to $832.8 million in 2022, then increased by 0.13% to $833.8 million in 2023, then grew by 15.8% to $965.6 million in 2024, then rose by 6.99% to $1.0 billion in 2025.
  • Its Current Assets was $1.0 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $968.6 million in Q1 2025.